CHECK-IN & COFFEE
8:00
WORKSHOP A
8:30
Advancing Precision Medicine in Neurodegenerative & Neuroinflammatory Disease: Subtyping & Biomarker Validation
Synopsis
As neurological disorders become better understood, defining disease subtypes and validating biomarkers that correlate with subtype pathology will be crucial in more effective patient treatment.
Learning from the five biological variants of Alzheimer’s Disease characterizing five molecular subtypes with distinct genetic risk profiles, how can we further differentiate heterogenous disease and copathologies and validate distinct biomarkers within these differing pathologies?
Join this session to:
- Delve into Alzheimer’s Disease subtyping across detrimental and inflammatory vs repair states
- Understand biomarker validation across Alzheimer’s Disease subtypes and need for both biological and clinical understanding
- Harness natural history studies to predict long term benefits of therapies in clinical development to identify the early divergence between neurodegeneration and neuroinflammation and prodromal disease
- Discussing strategies for defining synaptic markers of interest and developing clinical validation approaches that go beyond generalized disease metrics
- Exploring the utility of longitudinal datasets and precision medicine approaches in understanding neurodegenerative and neuroinflammatory subtypes and their associated biomarker profiles
- Reviewing the challenges and opportunities of translating biomarker discoveries into targeted therapeutics for improved clinical outcomes
- Creating biosignatures within smaller groups that are targetable by pharma companies for therapeutics to modulate biomarkers to show clinical benefit or trial utility
*Morning break & refreshments will be served during this session at 9:45am
Lorna Farrelly
Principal Scientist
Regeneron
Pharmaceuticals
Christopher Whelan
Director, Neuroscience Data Science
Johnson & Johnson
Wesley Horton
Program Manager
Digital Infuzion
Shane V. Hegarty
Chief Scientific Officer & Co-Founder
Axonis Therapeutics
SHORT REFRESHMENT BREAK
11:00
WORKSHOP B
11:15
Enriching Blood & CSF Data with Imaging Assays for Longitudinal & Sensitive Monitoring of Patient Benefit
Synopsis
With innovations in AI and omics technology opening the floodgates to biomarker breakthroughs for the CNS, how can we ensure biomarker discovery and validation is key in neuroscience? This session will explore how these innovative approaches are revolutionizing our understanding of complex neurological diseases and paving the way for precision medicine?
Join this session to:
• Learn about the latest high-throughput proteomics techniques uncovering novel protein biomarkers for neurodegenerative and neuroinflammatory diseases, to track disease trajectory, disease progression and broaden therapeutic targeting
• Explore the role of polygenic risk scores (PRS) in predicting disease risk and enabling earlier intervention strategies
• Explore metabolic profiling to reveal crucial metabolic changes linked to neurodegenerative diseases offering new avenues for therapeutic development
• Implementing ML/AI for disease progression modelling to detect early biomarkers and monitor disease states
*Lunch will be served during this session at 12:30pm
Pallavi Sachdev
Executive Director
Translational Science, Clinical
Evidence Generation, Deep
Human Biology (CEG DHBL)
Eisai
Ying Wu
Director & Head of
Human Genetics
Eisai
SHORT REFRESHMENT BREAK
2.15
WORKSHOP C
2.30
Enriching Blood & CSF Data with Imaging Assays for Longitudinal & Sensitive Monitoring of Patient Bene
Synopsis
As more sensitive tools become available for imaging, blood and CSF markers, how can drug developers most
efficiently integrate these measures to sensitively determine drug effect in trials while minimizing costs?
Join this session to:
• Choosing the most relevant fluid marker to validate your drug’s efficacy and mechanism of action in the clinic and support your BLA application for regulatory approval
• Harnessing blood-based markers and other biofluids for more longitudinal monitoring of patient improvement, while employing PET and MRI analysis for more sensitive mapping of disease progression and pathology
• Navigating patient selection for imaging cohorts to identify early stage ‘treatable’ patients and map pathological spread of neurodegeneration over time and higher return on investment for imaging data
• Exploring divergences in tracer and fluid ‘cut offs’ across different socioeconomic and ethnic groups impacting health and thus biomarker processing to impact thresholds
*Afternoon break & refreshments will be served during this session at 3:30
Cristian Salinas
Neuroscience Imaging
Lead, Clinical Imaging
Takeda
Carol Singh
Associate Director, Group
Lead, Sample & Data
Management
Takeda
